Navigation Links
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Date:9/30/2008

rams, and ability to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended June 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
2. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
3. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
8. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
9. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
10. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
11. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015  PAREXEL International Corporation (NASDAQ: ... and Fiscal Year 2015 on Wednesday, August 5 th , ... will be available on PAREXEL,s website at www.PAREXEL.com ... PAREXEL will host a conference call and live webcast ... 2015 to discuss the results.  To access the webcast, visit ...
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
(Date:7/7/2015)... , July 7, 2015 ... new generation of drugs within human and veterinary ... sales company in the United States ... Vet-CA1, its leading companion animal therapeutic. ... http://photos.prnewswire.com/prnh/20150703/228329 ) , Paccal ...
Breaking Medicine Technology:PAREXEL International Announces Date Of Fourth Quarter And Fiscal Year 2015 Earnings Release And Conference Call 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
... Londe, M.D. Contributing Editor The outcome of many illnesses ... (ICUs) has not improved dramatically over the past decades, ... and pharmacological support of vital organ systems. Indeed, ... five days have a 20 percent risk of death ...
... level of blood oxygenation can be an essential ... in the clinical setting is often desirable. In ... technology into easily used point-of-care devices, recent products ... values., ,HemoCue, Inc., Lake Forest, Calif., says that ...
Cached Medicine Technology:Tight Glycemic Control in the ICU 2Tight Glycemic Control in the ICU 3Hemoglobin Testing at the Point of Care 2Hemoglobin Testing at the Point of Care 3
(Date:7/7/2015)... ... July 07, 2015 , ... ... today announced that TimberNook ( http://www.timbernook.com/ ) has selected the agency ... and marketing launch package for new camp providers. TimberNook is a nature-based ...
(Date:7/7/2015)... ... July 07, 2015 , ... Isabel Healthcare ... announced a partnership focused on providing knowledge organizing and differential diagnostic support tools ... be conducted with NIWH trained patient health educators, utilizing the Knowledge Organizer and ...
(Date:7/7/2015)... MO (PRWEB) , ... July 07, 2015 , ... ... liability law announce the launch of their new website, the Invokana Ketoacidosis ... Invokana FDA warning*, and serves as a resource for persons wishing to learn ...
(Date:7/7/2015)... ... 2015 , ... CareSync proudly announces today that Amy Gleason, ... House as a “Champion of Change” for Precision Medicine on Wednesday, July 8th. ... Change program recognizes Gleason and eight other extraordinary individuals who are making great ...
(Date:7/6/2015)... ... 07, 2015 , ... Currently, mobile testing is one the ... in the molecular diagnostic technologies, wide availability of immunosuppressive drugs and bioterrorism threats ... genetic engineering also open lucrative opportunities for the market players. , However, there ...
Breaking Medicine News(10 mins):Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 2Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 3Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3
... , IRVINE, Calif., Aug. 25 CorVel ... Company,s Board of Directors has approved a 1,000,000 share expansion to ... approved for repurchase over the life of the program to 14,150,000 ... repurchase program in the fall of 1996. From the program,s inception ...
... New Single ... People to Sign Up to Donate Life - New CD - No Regrets In Stores ... Beverly Hills, ... smash with the song "I Swear," is returning to recording and performing after a seven-year ...
... , ROCKVILLE, Md., Aug. 25 ... for patients on behalf of both countries, the U.S. Pharmacopeial ... the United Mexican States (FEUM) today agreed to collaborate on ... key component of public health, helping to ensure the identity, ...
... , , , ... national nonprofit organization that helps people reclaim their lives from ... Foundation Relations. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/CGTU038LOGO ... "I,m very pleased to announce the appointment of William ...
... visitors to Indian subcontinent, CDC reports , TUESDAY, Aug. ... common cause of infection with an antimicrobial-resistant strain of ... new study finds. , About 300 cases of typhoid ... and the majority of these cases are associated with ...
... gender may be to blame, researchers say , TUESDAY, Aug. ... than men in the 30 days after a heart attack, ... new study finds. , Rather, "the difference can be attributed ... the presence of other illnesses, said study lead author Dr. ...
Cached Medicine News:Health News:CorVel Announces Expansion to Share Buyback Program 2Health News:CorVel Announces Expansion to Share Buyback Program 3Health News:R&B / Pop Vocal Quartet All-4-One Makes 7-Year Comeback 2Health News:R&B / Pop Vocal Quartet All-4-One Makes 7-Year Comeback 3Health News:Quality of Medicines Advanced by Agreement Between USP, Mexican Standards Body 2Health News:William C. Moyers Appointed Vice President of Foundation Relations for Hazelden 2Health News:International Travel Raises Risk of Typhoid 2Health News:Women More Prone to Die in Month After Heart Attack 2Health News:Women More Prone to Die in Month After Heart Attack 3
Replacement bulb for Vibratome light system....
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
... The Specimen Tray accessory fits inside the existing ... working area for tissue sectioning. Specimens are ... tray. This is a great option if ... expensive buffer, or wish to utilize the black ...
Medicine Products: